Brief: Vaccinex Announces Signing Of Two Multi-Project Deals With Leading Pharmaceutical Companies Focused On Leveraging Its Activmab Platform
19/02/2021 14:33
Feb 19 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX ANNOUNCES SIGNING OF TWO MULTI-PROJECT DEALS WITH
LEADING PHARMACEUTICAL COMPANIES FOCUSED ON LEVERAGING ITS
ACTIVMAB® PLATFORM
* VACCINEX INC - FINANCIAL TERMS OF DEALS ARE UNDISCLOSED
* VACCINEX - COLLABORATIONS WILL FOCUS ON USING ACTIVMAB FOR
ANTIBODY DISCOVERY AGAINST COMPLEX ANTIGENS SUCH AS GPCRS AND
ION CHANNELS
Source text for Eikon: ID:nGNX95r1RS
Further company coverage: VCNX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease